These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 21261567)
41. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives. Suzuki N; Hatta T; Ito M; Kusakabe KI Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936 [TBL] [Abstract][Full Text] [Related]
42. Application of immunosignatures to the assessment of Alzheimer's disease. Restrepo L; Stafford P; Magee DM; Johnston SA Ann Neurol; 2011 Aug; 70(2):286-95. PubMed ID: 21823156 [TBL] [Abstract][Full Text] [Related]
43. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Bales KR Expert Opin Drug Discov; 2012 Apr; 7(4):281-97. PubMed ID: 22458501 [TBL] [Abstract][Full Text] [Related]
46. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease. Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065 [TBL] [Abstract][Full Text] [Related]
47. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481 [TBL] [Abstract][Full Text] [Related]
48. Mechanisms of A beta plaque clearance following passive A beta immunization. Morgan D Neurodegener Dis; 2005; 2(5):261-6. PubMed ID: 16909007 [TBL] [Abstract][Full Text] [Related]
49. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322 [TBL] [Abstract][Full Text] [Related]
50. Vaccination strategies for Alzheimer's disease: A new hope? Woodhouse A; Dickson TC; Vickers JC Drugs Aging; 2007; 24(2):107-19. PubMed ID: 17313199 [TBL] [Abstract][Full Text] [Related]
51. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? Panza F; Solfrizzi V; Imbimbo BP; Logroscino G Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190 [TBL] [Abstract][Full Text] [Related]
52. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Geylis V; Steinitz M Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209 [TBL] [Abstract][Full Text] [Related]
53. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM; Hock C Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453 [TBL] [Abstract][Full Text] [Related]
54. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches. Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779 [TBL] [Abstract][Full Text] [Related]